Party Time: Brokers Just Made Major Increases To Their InnoCare Pharma Limited (HKG:9969) Earnings Forecasts
InnoCare Pharma Limited (HKG:9969) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts. The analysts greatly increased their revenue estimates, suggesting a stark improvement in business fundamentals.
Following the latest upgrade, the seven analysts covering InnoCare Pharma provided consensus estimates of CN¥2.6b revenue in 2026, which would reflect a perceptible 6.8% decline on its sales over the past 12 months. Statutory earnings per share are supposed to nosedive 63% to CN¥0.20 in the same period. Previously, the analysts had been modelling revenues of CN¥2.3b and earnings per share (EPS) of CN¥0.11 in 2026. There has definitely been an improvement in perception recently, with the analysts substantially increasing both their earnings and revenue estimates.
See our latest analysis for InnoCare Pharma
Despite these upgrades, the analysts have not made any major changes to their price target of CN¥17.35, suggesting that the higher estimates are not likely to have a long term impact on what the stock is worth. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on InnoCare Pharma, with the most bullish analyst valuing it at CN¥19.47 and the most bearish at CN¥14.71 per share. This is a very narrow spread of estimates, implying either that InnoCare Pharma is an easy company to value, or - more likely - the analysts are relying heavily on some key assumptions.
Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. These estimates imply that sales are expected to slow, with a forecast annualised revenue decline of 13% by the end of 2026. This indicates a significant reduction from annual growth of 28% over the last five years. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 21% annually for the foreseeable future. It's pretty clear that InnoCare Pharma's revenues are expected to perform substantially worse than the wider industry.
The Bottom Line
The most important thing to take away from this upgrade is that analysts upgraded their earnings per share estimates for this year, expecting improving business conditions. Fortunately, they also upgraded their revenue estimates, and are forecasting revenues to grow slower than the wider market. Some investors might be disappointed to see that the price target is unchanged, but we feel that improving fundamentals are usually a positive - assuming these forecasts are met! So InnoCare Pharma could be a good candidate for more research.
These earnings upgrades look like a sterling endorsement, but before diving in - you should know that we've spotted 3 potential flag with InnoCare Pharma, including concerns around earnings quality. For more information, you can click through to our platform to learn more about this and the 1 other flag we've identified .
Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies backed by insiders.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.